the role of jak inhibitors in treating mpns and the need for disease-modifying agents
Published 1 year ago • 110 plays • Length 4:42Download video MP4
Download video MP3
Similar videos
-
0:53
investigating the place of jak inhibitors in the treatment of myelofibrosis
-
2:42
hot topics in mpns: disease-modifying drugs, sequencing jak inhibitors and management of bp-mpns
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf
-
3:07
clinical guidance for the use of jak inhibitors when treating patients with mf
-
1:15
drugs under investigation for patients with mf who have failed treatment with jak inhibitors
-
3:48
jak inhibition for the early treatment of myelofibrosis
-
2:12
refine: phase ii study of navitoclax ruxolitinib in jak inhibitor-naive patients with mf
-
8:08
unravelling the mechanism of clots with jak inhibitors
-
13:48
understanding treatment options for et, pv, and myelofibrosis
-
1:19:17
an insider's look: innovations in malignant hematology research
-
2:52
jak inhibitor combination therapy for the treatment of myelofibrosis
-
2:23
factors to consider when selecting jak inhibitors for patients with mf
-
3:23
myelofibrosis: updates on jak inhibitors
-
3:21
looking beyond jak inhibitors: novel targeted therapies and strategies for mpn treatment
-
13:31
key highlights in mpns: novel agents, combinations, and the potential role of immunotherapy
-
0:46
xport-mf-034: selinexor plus ruxolitinib in jak-inhibitor naïve myelofibrosis
-
3:19
therapeutic options following failure to jak inhibitors
-
7:10
bomedemstat in jak inhibitor-resistant myelofibrosis
-
13:30
reviewing the role of jak inhibitors in atopic dermatitis
-
1:19
novel combination therapy for cmml: jak inhibitor pacritinib plus azacitidine
-
3:13
therapies for patients who progress on jak inhibitors: imetelstat, navtemadlin, selinexor & tp-3654
-
2:56
novel drugs for myeloma thromboprophylaxis